Skip to main content

Venous Leg Ulcer (VLU)

1
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Serena Group
Serena GroupMA - Cambridge
1 program
1
Intact Fish Skin GraftPhase 4
ConvaTec
ConvaTecNJ - Bridgewater
1 program
ConvaVAC™ Ag+ Negative Pressure Wound Therapy SystemN/A1 trial
Active Trials
NCT07342049Not Yet Recruiting87Est. Oct 2026
Biolab Pharma
Biolab PharmaBrazil - São Paulo
1 program
Tri-Membrane Wrap™N/A1 trial
Active Trials
NCT07078968Active Not Recruiting500Est. Oct 2025
MediWound
MediWoundYAVNE, Israel
1 program
EscharExPHASE_31 trial
Active Trials
NCT06568627Recruiting216Est. Mar 2027
Kerecis
KerecisIceland - Isafjordur
1 program
Intact Fish Skin GraftPHASE_41 trial
Active Trials
NCT06693570Recruiting150Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
KerecisIntact Fish Skin Graft
MediWoundEscharEx
ConvaTecConvaVAC™ Ag+ Negative Pressure Wound Therapy System
Biolab PharmaTri-Membrane Wrap™

Clinical Trials (4)

Total enrollment: 953 patients across 4 trials

NCT06693570KerecisIntact Fish Skin Graft

Evaluating Intact Fish Skin Graft and Standard of Care Versus Standard of Care Alone in Nonhealing Venous Leg Ulcers

Start: Nov 2024Est. completion: Nov 2026150 patients
Phase 4Recruiting

A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)

Start: Jun 2025Est. completion: Mar 2027216 patients
Phase 3Recruiting
NCT07342049ConvaTecConvaVAC™ Ag+ Negative Pressure Wound Therapy System

ConvaVAC™ Ag+ Negative Pressure Wound Therapy System in Chronic Wounds

Start: Jan 2026Est. completion: Oct 202687 patients
N/ANot Yet Recruiting
NCT07078968Biolab PharmaTri-Membrane Wrap™

A REAL WORLD DATA COLLECTION OF HUMAN AMNIOTIC MEMBRANE(S) ON DIABETIC FOOT ULCERS, VENOUS LEG ULCERS, PRESSURE ULCERS AND POST OPERATIVE WOUNDS

Start: Apr 2025Est. completion: Oct 2025500 patients
N/AActive Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 953 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.